Breakout sessions
FRIDAYMARCH 6
Morning SESSIONS
Sessions are 60 minutes beginning at 9:30 am – 10:30 am and repeated again at 10:45 am –11:45 am.
Oncology Practice of the Future
Marc Richmond
Regional Medical Director/Officer
Blue Shield California
- State of the art cancer care worthy of our families and friends respect for patient autonomy throughout care and end of life
- New compensation models which rewards quality and value
- Innovative technology using decision support which incorporates molecular markers and personalized therapy
Maximizing Effectiveness of Specialty Drugs through Innovative Collaboration Strategies
Kimberly Tuck
President and CEO
NurseWise, a subsidiary of Centene Corporation
- Positive clinical outcomes
- Positive patient experiences
- Increased provider satisfaction
- The opportunity to decrease downstream costs of complex, chronic conditions
Specialty pharmacy Integration: What it means and to whom
Michael White
Director, Clinical Pharmacy Services
BlueCross Blue Shield Tennessee
Peter Mikhail
Associate Vice President Procurement Services,
Geisinger Health System
The Role of the Payer post ACA…Challenges and Opportunities
Minalkumar Patel, M.D.
Senior Vice President and Chief Strategy Officer
Horizon Blue Cross Blue Shield, New Jersey
- Discuss how the payer landscape continues to evolve
- Identify specific challenges for success
- Determine long-term value drivers and impacts to the overall healthcare economy
Busting the Myths in Year 2 of the Exchanges
Sheri Sellmeyer
Vice President, Advisory Services
Decision Resources Group
Staying up to speed on exchange opportunities is a continuing challenge for pharma, further complicated by misleading prognosticators. In this session you will learn:
- How the exchanges are impacting payers’ bottom lines
- The real truth about movement to private exchanges
- What hybrid Medicaid/exchange programs mean for the market
- How competitive are the top players and new entries